Lyvup's platforms are developed within active clinical research programmes — not built first and validated later. This page describes our current research activity and the scientific principles that underpin what we build.
Most digital health companies develop technology and then seek clinical validation as a final step before commercialisation. Lyvup is structured differently. Our platforms are developed within funded, multi-institutional research programmes from the outset — with clinical partners, academic oversight, and peer-reviewed methodology as design constraints rather than afterthoughts.
Research partners are not reviewers of finished work — they are co-developers of the methodology, the intervention logic, and the validation design. The boundary between Lyvup's technology development and its partners' clinical research is deliberately blurred.
Both active research programmes were awarded through competitive grant processes — Horizon Europe and ZonMW — involving independent scientific review committees. The research questions were not designed around what Lyvup wanted to prove.
Results are published in peer-reviewed journals. Programmes currently in progress will produce publications as clinical phases complete. We will list outputs here as they appear — without anticipating findings that have not yet been independently validated.
Two funded research programmes are currently active. Both involve multi-institutional consortia with clinical and academic partners, and both are at stages of active data collection or platform development.
This programme addresses one of the most consequential gaps in cardiac care: the period between completion of supervised rehabilitation and long-term recovery maintenance. Most patients who complete a structured cardiac rehabilitation programme experience significant behavioural regression within the first year — not because the programme failed, but because no digital infrastructure exists to sustain its effect.
The programme develops and clinically validates a digital therapeutic intervention combining continuous remote monitoring, early relapse-risk detection, and personalised behavioural coaching. Lyvup is responsible for the scientific coordination and technological development of the programme across the European consortium.
A fundamental challenge in metabolic disease is that the same therapy produces radically different outcomes in patients with similar clinical profiles. Current treatment selection relies heavily on trial and error — with real costs in patient outcomes, adherence, and healthcare resources.
This programme develops a predictive stratification system for personalised metabolic therapy — combining continuous biosensor data, lifestyle and behavioural signals, and contextual factors to model individual variation in metabolic response. The consortium brings together clinical expertise (Amsterdam UMC), sensor and signal-processing research (TU Delft), AI and systems modelling (TU Eindhoven), and behavioural science (UvA), with Lyvup contributing the platform architecture and digital integration layer.
A ring-form-factor wearable for non-invasive continuous glucose monitoring — the sensor layer that underpins Lyvup's metabolic intelligence platform. Full technical documentation, including sensing architecture, signal processing methodology, validation strategy, and platform integration, is available on the Technology page.